Stefani Spranger on What Every Oncologist Should Know About Immunotherapy

Video

In Partnership With:

​Stefani Spranger, PhD, postdoctoral fellow, Cancer Research Institute at The University of Chicago, discusses the basic knowledge all oncologists should have regarding immunotherapy.

Stefani Spranger, PhD, postdoctoral fellow, Cancer Research Institute at The University of Chicago, discusses the basic knowledge all oncologists should have regarding immunotherapy.

Immunotherapy actives the immune system to recognize and then destroy the cancer, says Spranger. The main players in this recognition are CD8-positive T cells. These are the T cells in viral infections that are responsible for killing the infected cells.

With cancer, because the body’s own cells are attacking it, the CD8-positive T cells do not know to fight it. Immunotherapy educates the immune system to do this and could possibility be used to fight most of the cancers that are currently out there, says Spanger.

Related Videos
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
John M. Kirkwood, MD, Distinguished Service Professor of Medicine, Sandra and Thomas Usher Professor of Medicine, Dermatology & Translational Science, coleader, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, the University of Pittsburgh
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
William B. Pearse, MD
Daniel Olson, MD
Nan Chen, MD
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center
Akriti Jain, MD
Samer A. Srour, MB ChB, MS